San Carlos, United States
Logomix Biotechnology is reshaping the landscape of drug development with its pioneering approach to cellular system engineering. The company, founded in 2019 and headquartered in the United States, is marked by its commitment to transforming therapeutics into a scalable information science.
Central to their innovation is the proprietary Geno-Writing™ platform, which allows for the precise and expansive editing of the human genome. This technology is pivotal in Logomix's internal programs, such as their work on Type 1 Diabetes, and serves as a powerful tool for global partners tackling a variety of diseases. Beyond therapeutics, Geno-Writing™ also enhances the Bio-AI ecosystem by generating high-quality iPSC libraries for advanced cell modeling.
Logomix's recent financial milestone—a $3.90M Seed Round on 08 February 2023—was backed by prominent investors including JAFCO Japan, SandHill Angels, Angel Bridge, UTokyo Innovation Platform, and Yasunori Kaneko. This investment underscores confidence in Logomix's potential to industrialize drug discovery, shifting it from an unpredictable art to a reproducible science.
Kytopen